AI Article Synopsis

  • - A 55-year-old man with malignant melanoma had his eye removed and later developed liver metastasis, confirmed by biopsy after abnormal findings in a PET/CT scan.
  • - He initially received radiofrequency ablation therapy for his liver tumors, but experienced a recurrence and was referred for surgery due to the absence of effective medical treatments for this condition.
  • - The patient underwent partial hepatectomy to remove 14 tumors from his liver, followed by chemotherapy, but unfortunately died from hepatic failure nine months after the operation, highlighting the urgent need for more research on treatment options for metastatic melanoma.

Article Abstract

A 55-year-old man who underwent eye enucleation at our hospital's ophthalmology department was pathologically diagnosed with malignant melanoma. Four months later after diagnosis, he underwent positron emission tomography/computed tomography for detecting systemic metastasis. Abnormal accumulation was found in S4 of the liver. He was therefore referred to the gastrointestinal department, where liver metastasis from malignant melanoma was diagnosed by biopsy. He underwent radiofrequency ablation therapy. A recurrence 3 months later was judged difficult to manage medically. He was thus sent to our department. Preoperative magnetic resonance imaging revealed multiple tumors in both liver lobes. Thus far, no treatment strategy has been established for hepatic metastases of malignant melanoma. After receiving a thorough explanation, he agreed to partial hepatectomy. We identified 14 tumors by intraoperative ultrasonography as sites for partial hepatectomy. Postoperative chemotherapy was administered. He died of hepatic failure 9 months after the operation. It is necessary to accumulate further cases on a national scale, because establishment of appropriate therapy for this condition is urgently needed.

Download full-text PDF

Source

Publication Analysis

Top Keywords

malignant melanoma
16
liver metastasis
8
metastasis malignant
8
partial hepatectomy
8
[hepatectomy liver
4
malignant
4
melanoma
4
melanoma ocular
4
ocular choroid
4
choroid origin-a
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

NYU Grossman School of Medicine, New York, NY, USA; NYU, New York City, NY, USA.

Background: Astrocytes, a major glial cell in the central nervous system (CNS), can become reactive in response to inflammation or injury, and release toxic factors that kill specific subtypes of neurons. Over the past several decades, many groups report that reactive astrocytes are present in the brains of patients with Alzheimer's disease, as well as several other neurodegenerative diseases. In addition, reactive astrocyte sub-types most associated with these diseases are now reported to be present during CNS cancers of several types.

View Article and Find Full Text PDF

Outcomes of Immunotherapy Treatment in Sinonasal Mucosal Melanoma.

Am J Rhinol Allergy

January 2025

Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania.

Background: Sinonasal mucosal melanoma has poor survival despite multimodality treatment. While the impact of immunotherapy (IT) on metastatic cutaneous melanoma is well-defined, there are relatively little data on sinonasal mucosal melanoma.

Objective: We sought to define immunotherapy outcomes in patients with sinonasal mucosal melanoma.

View Article and Find Full Text PDF

Background: The metal oxide nanoparticles possess unique properties such as biological compatibility, superior reactivity, and capacity to develop reactive oxygen species, due to this they have drawn significant interest in cancer treatment. The various MONPs such as cerium oxide, Copper oxide, Iron oxide, Titanium dioxide, and Zinc oxide have been investigated for several types of cancers including brain, breast, cervical, colon, leukemia, liver, lung, melanoma, ovarian, and prostate cancers. However, traditional physiochemical synthetic methods for MONPs commonly include toxic materials, a major concern that raises questions regarding their biocompatibility and safety.

View Article and Find Full Text PDF

Single-cell analysis unveils cell subtypes of acral melanoma cells at the early and late differentiation stages.

J Cancer

January 2025

Department of Plastic and Reconstructive Surgery, Shanghai 9th People's Hospital, School of Medicine, Shanghai Jiao Tong University, 639 Zhi Zao Ju Rd, Shanghai, 200011, China.

Background: Melanoma, a malignant neoplasm originating from melanocytes, is a form of skin cancer with rapidly increasing global incidence, often exacerbated by UV radiation[1]. Particularly, acral melanoma, characterized by its swift metastasis and poor prognosis, underscores the significance of further research into its heterogeneity. Single-cell sequencing has been widely utilized in the study of tumor heterogeneity; however, research related to melanoma remains to be further refined.

View Article and Find Full Text PDF

Melanoma poses a significant challenge to patients due to its aggressive nature and limited treatment options. Recent studies have suggested that lasalocid, a feed additive ionophore antibiotic, may have potential as an anticancer agent. However, the mechanism of lasalocid in melanoma is unclear.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!